Blog
The need for opiate and drug testing has grown in the last three decades. 2.4 million people in the United States abused opioid pain relievers in 1985, the year before President Ronald Reagan announced his Federal Drug-Free Workplace Program.1 That number swelled to 4.9 million – a 104% increase – by 2012.2 During that same time, the population of the United States grew only 32%.
The original opiate testing panel created in 1986 is an incomplete tool for today’s drug testing needs. No other category of drugs has evolved as much as opiates and opioids. Addiction to high strength pain relievers and newer opioid compounds has eclipsed codeine, morphine, and heroin addiction addressed by the original 1986 five-panel drug test.
Based on the most recent data on emergency department visits related to illicit substance abuse, it is clear that opiate and opioid abuse has shifted dramatically. Screening for opiate abuse using only 1986 drug testing guidelines for the opiate drug class misses the past 30 years of pharmaceutical and drug testing advancements.3
References:
- Drug Classes and Neurotransmitters: Amphetamine, Cocaine, and Hallucinogens
- Environmental Exposure Testing for Delta-8 THC, Delta-9 THC, Delta-10 THC, and CBD
- Bromazolam and Synthetic Benzodiazepines
- Winter Weather Delay Update
- Tianeptine
- Revolutionizing DUI Interventions: Wisconsin’s Breakthrough in Biomarker Testing for Impaired Drivers
- 3 FAQs You Should Know About Newborn Drug Testing
- The Brain Chemistry Behind Tolerance and Withdrawal
- March 2024 (1)
- February 2024 (1)
- January 2024 (3)
- December 2023 (1)
- November 2023 (1)
- August 2023 (1)